Trial Profile
A Randomized, Double-Masked, Vehicle-Controlled Proof-Of-Concept Study for Topically Delivered LHA510 as a Maintenance Therapy in Patients With Wet Age-Related Macular Degeneration (AMD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Jul 2022
Price :
$35
*
At a glance
- Drugs LHA 510 (Primary) ; Ranibizumab
- Indications Wet age-related macular degeneration
- Focus Proof of concept; Therapeutic Use
- Sponsors Alcon
- 01 Jul 2022 Primary endpoint has not been met (Number of patients requiring Lucentis retreatment before or at Day 84) , according to Results published in the American Journal of Ophthalmology
- 01 Jul 2022 Results published in the American Journal of Ophthalmology
- 24 Oct 2016 Status changed from active, no longer recruiting to completed.